Immunic, Inc. (NASDAQ:IMUX - Free Report) - Equities researchers at Brookline Capital Markets decreased their FY2026 EPS estimates for Immunic in a report released on Friday, November 13th. Brookline Capital Markets analyst F. Ahmed now anticipates that the company will post earnings of ($4.39) per share for the year, down from their prior estimate of ($3.86). The consensus estimate for Immunic's current full-year earnings is ($3.69) per share. Brookline Capital Markets also issued estimates for Immunic's Q4 2026 earnings at ($1.51) EPS.
A number of other brokerages also recently commented on IMUX. Weiss Ratings restated a "sell (d-)" rating on shares of Immunic in a research note on Wednesday, August 26th. Cantor Fitzgerald began coverage on shares of Immunic in a research report on Friday, October 23rd. They set an "overweight" rating on the stock. Roth Capital reaffirmed a "buy" rating on shares of Immunic in a research note on Tuesday, September 1st. Wall Street Zen downgraded shares of Immunic from a "sell" rating to a "strong sell" rating in a research note on Saturday. Finally, Zacks Research lowered Immunic from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 10th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Immunic currently has an average rating of "Moderate Buy" and an average target price of $35.43.
View Our Latest Stock Analysis on IMUX
Immunic Price Performance
Shares of IMUX opened at $7.33 on Wednesday. The firm has a market capitalization of $116.40 million, a price-to-earnings ratio of -1.80 and a beta of 1.48. Immunic has a 1-year low of $5.06 and a 1-year high of $17.43. The company has a 50-day moving average of $8.47 and a 200 day moving average of $11.53.
Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.20).
Hedge Funds Weigh In On Immunic
Several institutional investors have recently made changes to their positions in IMUX. Aberdeen Group plc increased its stake in shares of Immunic by 32.3% during the third quarter. Aberdeen Group plc now owns 1,090,427 shares of the company's stock valued at $10,141,000 after buying an additional 266,034 shares during the period. Braidwell LP bought a new stake in shares of Immunic in the second quarter valued at about $9,914,000. Avidity Partners Management LP lifted its stake in Immunic by 42.6% in the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company's stock worth $7,436,000 after acquiring an additional 2,000,000 shares during the period. Marshall Wace LLP lifted its stake in Immunic by 242.8% in the third quarter. Marshall Wace LLP now owns 359,319 shares of the company's stock worth $3,342,000 after acquiring an additional 254,503 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in Immunic in the first quarter worth about $1,020,000. Hedge funds and other institutional investors own 51.82% of the company's stock.
Trending Headlines about Immunic
Here are a few of the latest headlines about IMUX:
- Positive Sentiment: HC Wainwright, which maintains a “Buy” rating and $22 price target, raised its 2027 EPS estimate to a loss of $2.27 per share from $2.47 and its fourth-quarter 2026 estimate to a loss of $0.56 from $0.68.
- Negative Sentiment: HC Wainwright lowered its estimates for 2026, 2028, 2029 and 2030, while Brookline Capital Markets also reduced its 2026 and fourth-quarter 2026 forecasts. The downward revisions point to expectations of greater losses than previously projected.
- Negative Sentiment: Wall Street Zen cut Immunic to “Strong Sell,” adding a bearish rating signal. Immunic NASDAQ: IMUX Cut to “Strong Sell” at Wall Street Zen
About Immunic
(
Get Free Report)
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company's research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.